Pfizer's Tilrekimig Meets Phase 2 Primary Endpoint In Atopic Dermatitis

Pfizer reported that its ongoing Phase 2 trial of investigational Tilrekimig met its primary endpoint in adults with moderate-to-severe atopic dermatitis. The positive mid-stage clinical result supports continued development of the therapy, though the article provided no efficacy magnitude, safety data, or commercialization timeline.